@article {1172381,
	title = {MicroRNA therapeutics: towards a new era for the management of cancer and other diseases},
	journal = {Nat Rev Drug Discov},
	volume = {16},
	number = {3},
	year = {2017},
	month = {2017 Mar},
	pages = {203-222},
	abstract = {In just over two decades since the discovery of the first microRNA (miRNA), the field of miRNA biology has expanded considerably. Insights into the roles of miRNAs in development and disease, particularly in cancer, have made miRNAs attractive tools and targets for novel therapeutic approaches. Functional studies have confirmed that miRNA dysregulation is causal in many cases of cancer, with miRNAs acting as tumour suppressors or oncogenes (oncomiRs), and miRNA mimics and molecules targeted at miRNAs (antimiRs) have shown promise in preclinical development. Several miRNA-targeted therapeutics have reached clinical development, including a mimic of the tumour suppressor miRNA miR-34, which reached phase I clinical trials for treating cancer, and antimiRs targeted at miR-122, which reached phase II trials for treating hepatitis. In this article, we describe recent advances in our understanding of miRNAs in cancer and in other diseases and provide an overview of current miRNA therapeutics in the clinic. We also discuss the challenge of identifying the most efficacious therapeutic candidates and provide a perspective on achieving safe and targeted delivery of miRNA therapeutics.},
	keywords = {Animals, Clinical Trials as Topic, Disease Management, Genetic Therapy, Humans, MicroRNAs, Neoplasms},
	issn = {1474-1784},
	doi = {10.1038/nrd.2016.246},
	author = {Rupaimoole, Rajesha and Slack, Frank J}
}
